Immunosurveillance  ||| S:0 E:19 ||| NNP
and  ||| S:19 E:23 ||| CC
immunoediting--can  ||| S:23 E:42 ||| JJ
the  ||| S:42 E:46 ||| DT
immune  ||| S:46 E:53 ||| JJ
response  ||| S:53 E:62 ||| NN
be  ||| S:62 E:65 ||| VB
made  ||| S:65 E:70 ||| VBN
more  ||| S:70 E:75 ||| JJR
immunodemocratic ||| S:75 E:91 ||| NN
?  ||| S:91 E:93 ||| .
Increasing  ||| S:93 E:104 ||| VBG
evidence  ||| S:104 E:113 ||| NN
has  ||| S:113 E:117 ||| VBZ
demonstrated  ||| S:117 E:130 ||| VBN
that  ||| S:130 E:135 ||| IN
the  ||| S:135 E:139 ||| DT
immune  ||| S:139 E:146 ||| JJ
system  ||| S:146 E:153 ||| NN
is  ||| S:153 E:156 ||| VBZ
able  ||| S:156 E:161 ||| JJ
to  ||| S:161 E:164 ||| TO
mount  ||| S:164 E:170 ||| VB
responses  ||| S:170 E:180 ||| NNS
against  ||| S:180 E:188 ||| IN
tumors  ||| S:188 E:195 ||| NNS
and  ||| S:195 E:199 ||| CC
that  ||| S:199 E:204 ||| IN
these  ||| S:204 E:210 ||| DT
responses  ||| S:210 E:220 ||| NNS
can  ||| S:220 E:224 ||| MD
be  ||| S:224 E:227 ||| VB
enhanced  ||| S:227 E:236 ||| VBN
using  ||| S:236 E:242 ||| VBG
a  ||| S:242 E:244 ||| DT
number  ||| S:244 E:251 ||| NN
of  ||| S:251 E:254 ||| IN
strategies ||| S:254 E:264 ||| NNS
.  ||| S:264 E:266 ||| .
Several  ||| S:266 E:274 ||| JJ
of  ||| S:274 E:277 ||| IN
these  ||| S:277 E:283 ||| DT
strategies  ||| S:283 E:294 ||| NNS
are  ||| S:294 E:298 ||| VBP
currently  ||| S:298 E:308 ||| RB
being  ||| S:308 E:314 ||| VBG
evaluated  ||| S:314 E:324 ||| VBN
in  ||| S:324 E:327 ||| IN
clinical  ||| S:327 E:336 ||| JJ
trials ||| S:336 E:342 ||| NNS
,  ||| S:342 E:344 ||| ,
where  ||| S:344 E:350 ||| WRB
their  ||| S:350 E:356 ||| PRP$
efficacy  ||| S:356 E:365 ||| NN
and  ||| S:365 E:369 ||| CC
cost  ||| S:369 E:374 ||| NN
effectiveness  ||| S:374 E:388 ||| NN
will  ||| S:388 E:393 ||| MD
be  ||| S:393 E:396 ||| VB
ascertained ||| S:396 E:407 ||| NNS
.  ||| S:407 E:409 ||| .
Sadly ||| S:409 E:414 ||| RB
,  ||| S:414 E:416 ||| ,
we  ||| S:416 E:419 ||| PRP
have  ||| S:419 E:424 ||| VBP
to  ||| S:424 E:427 ||| TO
admit  ||| S:427 E:433 ||| VB
that  ||| S:433 E:438 ||| IN
despite  ||| S:438 E:446 ||| IN
great  ||| S:446 E:452 ||| JJ
expectations  ||| S:452 E:465 ||| NNS
and  ||| S:465 E:469 ||| CC
enormous  ||| S:469 E:478 ||| JJ
achievements  ||| S:478 E:491 ||| NNS
in  ||| S:491 E:494 ||| IN
basic  ||| S:494 E:500 ||| JJ
immunology  ||| S:500 E:511 ||| NN
and  ||| S:511 E:515 ||| CC
molecular  ||| S:515 E:525 ||| JJ
biology ||| S:525 E:532 ||| NN
,  ||| S:532 E:534 ||| ,
immunotherapeutic  ||| S:534 E:552 ||| JJ
interventions  ||| S:552 E:566 ||| NNS
relying  ||| S:566 E:574 ||| VBG
on  ||| S:574 E:577 ||| IN
the  ||| S:577 E:581 ||| DT
elicitation  ||| S:581 E:593 ||| NN
of  ||| S:593 E:596 ||| IN
cytotoxic  ||| S:596 E:606 ||| JJ
cellular  ||| S:606 E:615 ||| JJ
immunity  ||| S:615 E:624 ||| NN
so  ||| S:624 E:627 ||| RB
far  ||| S:627 E:631 ||| RB
have  ||| S:631 E:636 ||| VBP
had  ||| S:636 E:640 ||| VBN
limited  ||| S:640 E:648 ||| JJ
success ||| S:648 E:655 ||| NN
.  ||| S:655 E:657 ||| .
We  ||| S:657 E:660 ||| PRP
have  ||| S:660 E:665 ||| VBP
found  ||| S:665 E:671 ||| VBN
that  ||| S:671 E:676 ||| IN
gene-based  ||| S:676 E:687 ||| JJ
vaccination  ||| S:687 E:699 ||| NN
is  ||| S:699 E:702 ||| VBZ
effective  ||| S:702 E:712 ||| JJ
in  ||| S:712 E:715 ||| IN
breaking  ||| S:715 E:724 ||| VBG
tolerance  ||| S:724 E:734 ||| NN
to  ||| S:734 E:737 ||| TO
tumor-associated  ||| S:737 E:754 ||| JJ
antigens ||| S:754 E:762 ||| NN
,  ||| S:762 E:764 ||| ,
but  ||| S:764 E:768 ||| CC
the  ||| S:768 E:772 ||| DT
response  ||| S:772 E:781 ||| NN
is  ||| S:781 E:784 ||| VBZ
directed  ||| S:784 E:793 ||| VBN
towards  ||| S:793 E:801 ||| IN
few  ||| S:801 E:805 ||| JJ
of  ||| S:805 E:808 ||| IN
the  ||| S:808 E:812 ||| DT
potential  ||| S:812 E:822 ||| JJ
epitopes  ||| S:822 E:831 ||| JJ
due  ||| S:831 E:835 ||| JJ
to  ||| S:835 E:838 ||| TO
immunodominance ||| S:838 E:853 ||| VB
.  ||| S:853 E:855 ||| .
Tumor  ||| S:855 E:861 ||| NN
cells  ||| S:861 E:867 ||| NNS
that  ||| S:867 E:872 ||| WDT
have  ||| S:872 E:877 ||| VBP
lost  ||| S:877 E:882 ||| VBN
the  ||| S:882 E:886 ||| DT
immunodominant  ||| S:886 E:901 ||| JJ
epitope  ||| S:901 E:909 ||| JJ
due  ||| S:909 E:913 ||| JJ
to  ||| S:913 E:916 ||| TO
mutations  ||| S:916 E:926 ||| NNS
would  ||| S:926 E:932 ||| MD
no  ||| S:932 E:935 ||| RB
longer  ||| S:935 E:942 ||| RB
be  ||| S:942 E:945 ||| VB
recognized  ||| S:945 E:956 ||| VBN
and  ||| S:956 E:960 ||| CC
would  ||| S:960 E:966 ||| MD
evade  ||| S:966 E:972 ||| VB
immune  ||| S:972 E:979 ||| JJ
surveillance ||| S:979 E:991 ||| NN
.  ||| S:991 E:993 ||| .
Designing  ||| S:993 E:1003 ||| VBG
a  ||| S:1003 E:1005 ||| DT
protocol  ||| S:1005 E:1014 ||| NN
for  ||| S:1014 E:1018 ||| IN
immunotherapy ||| S:1018 E:1031 ||| NN
,  ||| S:1031 E:1033 ||| ,
therefore ||| S:1033 E:1042 ||| RB
,  ||| S:1042 E:1044 ||| ,
necessitates  ||| S:1044 E:1057 ||| JJ
stimulation  ||| S:1057 E:1069 ||| NN
of  ||| S:1069 E:1072 ||| IN
an  ||| S:1072 E:1075 ||| DT
immune  ||| S:1075 E:1082 ||| JJ
response  ||| S:1082 E:1091 ||| NN
directed  ||| S:1091 E:1100 ||| VBN
against  ||| S:1100 E:1108 ||| IN
a  ||| S:1108 E:1110 ||| DT
multitude  ||| S:1110 E:1120 ||| NN
of  ||| S:1120 E:1123 ||| IN
epitopes ||| S:1123 E:1131 ||| NN
.  ||| S:1131 E:1133 ||| .
Increasing  ||| S:1133 E:1144 ||| VBG
the  ||| S:1144 E:1148 ||| DT
number  ||| S:1148 E:1155 ||| NN
of  ||| S:1155 E:1158 ||| IN
epitopes  ||| S:1158 E:1167 ||| JJ
available  ||| S:1167 E:1177 ||| JJ
for  ||| S:1177 E:1181 ||| IN
presentation  ||| S:1181 E:1194 ||| NN
to  ||| S:1194 E:1197 ||| TO
T  ||| S:1197 E:1199 ||| NN
cells  ||| S:1199 E:1205 ||| NNS
is  ||| S:1205 E:1208 ||| VBZ
the  ||| S:1208 E:1212 ||| DT
initial  ||| S:1212 E:1220 ||| JJ
step ||| S:1220 E:1224 ||| NN
.  ||| S:1224 E:1226 ||| .
It  ||| S:1226 E:1229 ||| PRP
mandates  ||| S:1229 E:1238 ||| VBZ
increased  ||| S:1238 E:1248 ||| VBN
degradation  ||| S:1248 E:1260 ||| NN
of  ||| S:1260 E:1263 ||| IN
the  ||| S:1263 E:1267 ||| DT
antigen  ||| S:1267 E:1275 ||| NN
following  ||| S:1275 E:1285 ||| VBG
DNA  ||| S:1285 E:1289 ||| NN
immunization ||| S:1289 E:1301 ||| NN
.  ||| S:1301 E:1303 ||| .
A  ||| S:1303 E:1305 ||| DT
logical  ||| S:1305 E:1313 ||| JJ
continuation  ||| S:1313 E:1326 ||| NN
involves  ||| S:1326 E:1335 ||| VBZ
manipulation  ||| S:1335 E:1348 ||| NN
of  ||| S:1348 E:1351 ||| IN
the  ||| S:1351 E:1355 ||| DT
intimate  ||| S:1355 E:1364 ||| JJ
mechanisms  ||| S:1364 E:1375 ||| NNS
controlling  ||| S:1375 E:1387 ||| VBG
the  ||| S:1387 E:1391 ||| DT
processes  ||| S:1391 E:1401 ||| NNS
of  ||| S:1401 E:1404 ||| IN
stimulation  ||| S:1404 E:1416 ||| NN
and ||| S:1416 E:1419 ||| CC
/ ||| S:1419 E:1420 ||| NNP
or  ||| S:1420 E:1423 ||| CC
suppression  ||| S:1423 E:1435 ||| NN
of  ||| S:1435 E:1438 ||| IN
T  ||| S:1438 E:1440 ||| NN
cells  ||| S:1440 E:1446 ||| NNS
recognizing  ||| S:1446 E:1458 ||| VBG
the  ||| S:1458 E:1462 ||| DT
sub-dominant  ||| S:1462 E:1475 ||| JJ
epitopes  ||| S:1475 E:1484 ||| NNS
thus  ||| S:1484 E:1489 ||| RB
offering  ||| S:1489 E:1498 ||| VBG
to  ||| S:1498 E:1501 ||| TO
the  ||| S:1501 E:1505 ||| DT
immunologist  ||| S:1505 E:1518 ||| JJ
ways  ||| S:1518 E:1523 ||| NNS
for  ||| S:1523 E:1527 ||| IN
overcoming  ||| S:1527 E:1538 ||| JJ
tumor-immune  ||| S:1538 E:1551 ||| JJ
evasion  ||| S:1551 E:1559 ||| NN
strategies ||| S:1559 E:1569 ||| NNS
.  ||| S:1569 E:1571 ||| .
We  ||| S:1571 E:1574 ||| PRP
now  ||| S:1574 E:1578 ||| RB
have  ||| S:1578 E:1583 ||| VB
the  ||| S:1583 E:1587 ||| DT
necessary  ||| S:1587 E:1597 ||| JJ
instruments  ||| S:1597 E:1609 ||| NNS
to  ||| S:1609 E:1612 ||| TO
ask  ||| S:1612 E:1616 ||| VB
all  ||| S:1616 E:1620 ||| PDT
the  ||| S:1620 E:1624 ||| DT
fundamental  ||| S:1624 E:1636 ||| JJ
questions  ||| S:1636 E:1646 ||| NNS
of  ||| S:1646 E:1649 ||| IN
tumor  ||| S:1649 E:1655 ||| NN
immunology ||| S:1655 E:1665 ||| NN
.  ||| S:1665 E:1667 ||| .
A  ||| S:1667 E:1669 ||| DT
better  ||| S:1669 E:1676 ||| JJR
understanding  ||| S:1676 E:1690 ||| NN
of  ||| S:1690 E:1693 ||| IN
the  ||| S:1693 E:1697 ||| DT
immune  ||| S:1697 E:1704 ||| JJ
escape  ||| S:1704 E:1711 ||| NN
mechanisms  ||| S:1711 E:1722 ||| NNS
and  ||| S:1722 E:1726 ||| CC
those  ||| S:1726 E:1732 ||| DT
underlying  ||| S:1732 E:1743 ||| JJ
tumor-induced  ||| S:1743 E:1757 ||| JJ
immune  ||| S:1757 E:1764 ||| JJ
suppression  ||| S:1764 E:1776 ||| NN
will  ||| S:1776 E:1781 ||| MD
help  ||| S:1781 E:1786 ||| VB
in  ||| S:1786 E:1789 ||| IN
designing  ||| S:1789 E:1799 ||| VBG
novel  ||| S:1799 E:1805 ||| NN
and  ||| S:1805 E:1809 ||| CC
more  ||| S:1809 E:1814 ||| RBR
efficient  ||| S:1814 E:1824 ||| JJ
protocols  ||| S:1824 E:1834 ||| NNS
for  ||| S:1834 E:1838 ||| IN
immunotherapy  ||| S:1838 E:1852 ||| NN
in  ||| S:1852 E:1855 ||| IN
the  ||| S:1855 E:1859 ||| DT
clinical  ||| S:1859 E:1868 ||| JJ
setting ||| S:1868 E:1875 ||| NN
.  ||| S:1875 E:1877 ||| .
